Literature DB >> 17690869

Serotonin transporter binding after recovery from eating disorders.

Ursula F Bailer1, Guido K Frank, Shannan E Henry, Julie C Price, Carolyn C Meltzer, Carl Becker, Scott K Ziolko, Chester A Mathis, Angela Wagner, Nicole C Barbarich-Marsteller, Karen Putnam, Walter H Kaye.   

Abstract

RATIONALE: Several lines of evidence suggest that altered serotonin (5-HT) function persists after recovery from anorexia nervosa (AN) and bulimia nervosa (BN).
OBJECTIVES: We compared 11 subjects who recovered (>1 year normal weight, regular menstrual cycles, no binging or purging) from restricting-type AN (REC RAN), 7 who recovered from bulimia-type AN (REC BAN), 9 who recovered from BN (REC BN), and 10 healthy control women (CW).
MATERIALS AND METHODS: Positron emission tomography (PET) imaging with [11C]McN5652 was used to assess the 5-HT transporter (5-HTT). For [11C]McN5652, distribution volume (DV) values were determined using a two-compartment, three-parameter tracer kinetic model, and specific binding was assessed using the binding potential (BP, BP=DVregion of interest/DVcerebellum-1).
RESULTS: After correction for multiple comparisons, the four groups showed significant (p<0.05) differences for [11C]McN5652 BP values for the dorsal raphe and antero-ventral striatum (AVS). Post-hoc analysis revealed that REC RAN had significantly increased [11C]McN5652 BP compared to REC BAN in these regions.
CONCLUSIONS: Divergent 5-HTT activity in subtypes of eating disorder subjects may provide important insights as to why these groups have differences in affective regulation and impulse control.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690869     DOI: 10.1007/s00213-007-0896-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  73 in total

1.  In vivo inhibition of neuronal activity in the rat ventromedial prefrontal cortex by midbrain-raphe nuclei: role of 5-HT1A receptors.

Authors:  Mihály Hajós; Sarah E Gartside; Viktor Varga; Trevor Sharp
Journal:  Neuropharmacology       Date:  2003-07       Impact factor: 5.250

2.  Serotonin transporter polymorphism and potential response to SSRIs in bulimia nervosa.

Authors:  P Monteleone; P Santonastaso; A Tortorella; A Favaro; M Fabrazzo; E Castaldo; L Caregaro; A Fuschino; M Maj
Journal:  Mol Psychiatry       Date:  2005-08       Impact factor: 15.992

3.  Personality traits after recovery from eating disorders: do subtypes differ?

Authors:  Angela Wagner; Nicole C Barbarich-Marsteller; Guido K Frank; Ursula F Bailer; Stephen A Wonderlich; Ross D Crosby; Shannan E Henry; Victoria Vogel; Katherine Plotnicov; Claire McConaha; Walter H Kaye
Journal:  Int J Eat Disord       Date:  2006-05       Impact factor: 4.861

Review 4.  Psychopharmacologic treatment of bulimia nervosa.

Authors:  B T Walsh
Journal:  J Clin Psychiatry       Date:  1991-10       Impact factor: 4.384

5.  In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652.

Authors:  R V Parsey; L S Kegeles; D R Hwang; N Simpson; A Abi-Dargham; O Mawlawi; M Slifstein; R L Van Heertum; J J Mann; M Laruelle
Journal:  J Nucl Med       Date:  2000-09       Impact factor: 10.057

6.  Analysis of the serotonin transporter gene linked polymorphism (5-HTTLPR) in anorexia nervosa.

Authors:  D Sundaramurthy; L F Pieri; H Gape; A F Markham; D A Campbell
Journal:  Am J Med Genet       Date:  2000-02-07

Review 7.  Eating disorders: progress and problems.

Authors:  B T Walsh; M J Devlin
Journal:  Science       Date:  1998-05-29       Impact factor: 47.728

8.  Brain mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion.

Authors:  K A Smith; J S Morris; K J Friston; P J Cowen; R J Dolan
Journal:  Br J Psychiatry       Date:  1999-06       Impact factor: 9.319

9.  Exaggerated 5-HT1A but normal 5-HT2A receptor activity in individuals ill with anorexia nervosa.

Authors:  Ursula F Bailer; Guido K Frank; Shannan E Henry; Julie C Price; Carolyn C Meltzer; Chester A Mathis; Angela Wagner; Laura Thornton; Jessica Hoge; Scott K Ziolko; Carl R Becker; Claire W McConaha; Walter H Kaye
Journal:  Biol Psychiatry       Date:  2007-01-22       Impact factor: 13.382

Review 10.  Serotonin transporter: gene, genetic disorders, and pharmacogenetics.

Authors:  Dennis L Murphy; Alicja Lerner; Gary Rudnick; Klaus-Peter Lesch
Journal:  Mol Interv       Date:  2004-04
View more
  24 in total

Review 1.  Antipsychotic agents in the treatment of anorexia nervosa: neuropsychopharmacologic rationale and evidence from controlled trials.

Authors:  Timothy D Brewerton
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

2.  5-HT₁A receptor binding is increased after recovery from bulimia nervosa compared to control women and is associated with behavioral inhibition in both groups.

Authors:  Ursula F Bailer; Cinnamon S Bloss; Guido K Frank; Julie C Price; Carolyn C Meltzer; Chester A Mathis; Mark A Geyer; Angela Wagner; Carl R Becker; Nicholas J Schork; Walter H Kaye
Journal:  Int J Eat Disord       Date:  2010-09-24       Impact factor: 4.861

Review 3.  Current status of functional imaging in eating disorders.

Authors:  Guido K W Frank; Walter H Kaye
Journal:  Int J Eat Disord       Date:  2012-04-25       Impact factor: 4.861

4.  Serotonin transporter binding in eating disorders.

Authors:  Per Södersten; Cecilia Bergh
Journal:  Psychopharmacology (Berl)       Date:  2007-12-31       Impact factor: 4.530

5.  A comprehensive treatment service must include developmental, systemic and collaborative components.

Authors:  Bryan Lask
Journal:  World Psychiatry       Date:  2009-10       Impact factor: 49.548

6.  Serotonin transporter binding after recovery from bulimia nervosa.

Authors:  Rama Pichika; Monte S Buchsbaum; Ursula Bailer; Carl Hoh; Alex Decastro; Bradley R Buchsbaum; Walter Kaye
Journal:  Int J Eat Disord       Date:  2011-06-13       Impact factor: 4.861

7.  The 5-HTTLPR polymorphism, platelet serotonin transporter activity and platelet serotonin content in underweight and weight-recovered females with anorexia nervosa.

Authors:  Stefan Ehrlich; Leonora Franke; Susann Scherag; Roland Burghardt; Regina Schott; Nora Schneider; Simone Brockhaus; Jakob Hein; Ralf Uebelhack; Ulrike Lehmkuhl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-12-03       Impact factor: 5.270

Review 8.  Cognitive Neuroscience of Eating Disorders.

Authors:  Joanna E Steinglass; Laura A Berner; Evelyn Attia
Journal:  Psychiatr Clin North Am       Date:  2018-12-03

9.  Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa.

Authors:  Ursula F Bailer; Guido K Frank; Julie C Price; Carolyn C Meltzer; Carl Becker; Chester A Mathis; Angela Wagner; Nicole C Barbarich-Marsteller; Cinnamon S Bloss; Karen Putnam; Nicholas J Schork; Anthony Gamst; Walter H Kaye
Journal:  Psychiatry Res       Date:  2012-11-13       Impact factor: 3.222

Review 10.  Nothing tastes as good as skinny feels: the neurobiology of anorexia nervosa.

Authors:  Walter H Kaye; Christina E Wierenga; Ursula F Bailer; Alan N Simmons; Amanda Bischoff-Grethe
Journal:  Trends Neurosci       Date:  2013-01-18       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.